MD-RA-102 "Prevention and Managment of Toxicities Associated with Disease Modifying Therapies"

Supported by an Educational Grant from: Mallinckrodt Pharmaceuticals

TITLE - Prevention and Management of Toxicities Associated with Disease Modifying Therapies

TARGET AUDIENCE - Pharmacists, Specialty Pharmacists, and other healthcare professionals

LEARNING OBJECTIVES - After completing the program, Pharmacists and Specialty Pharmacists along with other healthcare practitioner participants will be able to:

  1. Identify patient characteristics that increase the risk for developing toxicities with specific disease modifying therapies 
  2. Design appropriate strategies to minimize risk of toxicities associated with disease modifying therapies
  3. Recommend appropriate management of toxicities associated with individual agents
  4. Describe alternative agents for patients experiencing intolerable toxicities
  5. Identify the most common barriers for management of toxicities with regimens for rheumatoid arthritis

Faculty Disclosures:

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/ services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by the Specialty Pharma Education Center for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Pharmacist continuing education credit

Specialty Pharma Education Center (SPEC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hour (0.1CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
ACPE #0535-0000-17-002-H01-P

Knowledge Based Activity

Course release date 2/7/2017

Course expires 2/7/2020

Credit Information

Activity Number Credit Amount Accreditation Period
0535-0000-17-002-H01-P 0.1 CEUs February 07, 2017 - February 07, 2020